- Paperback: 196 pages
- Publisher: Routledge; 1 edition (March 11, 2004)
- Language: English
- ISBN-10: 0789023997
- ISBN-13: 978-0789023995
- Product Dimensions: 6 x 0.5 x 8.4 inches
- Shipping Weight: 10.6 ounces (View shipping rates and policies)
- Average Customer Review: 4.0 out of 5 stars See all reviews (1 customer review)
- Amazon Best Sellers Rank: #3,734,092 in Books (See Top 100 in Books)
Enter your mobile number or email address below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.
To get the free app, enter your mobile phone number.
Cannabis: From Pariah to Prescription 1st Edition
Use the Amazon App to scan ISBNs and compare prices.
The Amazon Book Review
Author interviews, book reviews, editors picks, and more. Read it now
Frequently bought together
Customers who viewed this item also viewed
EDUCATIONAL AND PROVOCATIVE. . . . EXTREMELY TIMELY. . . . A compendium of clinical studies conducted by GW Pharmaceuticals -- Ken Mackie, MD, Professor or Anesthesiology, Adjunct Professor of Physiology & Biophysics, University of Washington School of Medicine, Seattle
IMPORTANT AND COMPREHENSIVE conclusions contained in this work are CRUCIAL TO ADVANCEMENT IN OUR KNOWLEDGE OF CANNABIS AS PRESCRIPTION MEDICINE -- Senator Pierre Claude Nolin, Conservative Party, Canada --This text refers to the Hardcover edition.
Browse award-winning titles. See more
If you are a seller for this product, would you like to suggest updates through seller support?
Top customer reviews
It is mostly aimed at making widely available the results of the careful clinical trials of cannabinoid sprays(ie, solutions for spraying in the nose or mouth, not smoke or tablets) in humans done by GW Pharmaceuticals in the UK as a necessary preliminary to putting their groundbreaking products on the market. Russos three excellent articles at the beginning and end provide a contrast to the three very dry but necessary and precise clinical articles.
It is certain that there must be many disease states associated with the endogenous cannabinoids. Russo and GW are the first to to controlled clinical experiments on solutions of cannabidiol and THC together. As I pointed out in my own book on marijuana chemistry 30 years ago, this is critical as CBD is always present in natural marijuana and it modulates the effects of THC. Other researchers have never used them separate or together in a spray form. This is critical as both smoke and pill forms are nearly impossible to control and titrate and this has been a major barrier to medical use. In this way , GW Pharmaceuticals hopes to make a major impact on the medical use of cannabinoids and have entered them into the drug licensing process in many countries as treatments for multiple sclerosis and other problems.
An enormous amount of research is in process on synthetic, marijuana derived and endogenous cannabinoids. This is primarily due to the discovery of the endogenous anandamides and their receptors. There are thousands of compounds that can stimulate and inhibit the activity of CB1 and CB2 receptors and the list of potential therapeutic actions is nearly coextensive with human physiology, behavior and disease. GW has greatly stimulated this field by developing advanced oral applicators which can carefully monitor the dosing and even send the data wirelessly to a central data collection point in a hospital or over the net.
Because of their wide range of actions and extremely low toxicity, it is likely that there will be numerous applications for cannabinoids including many in pediatrics and pregnancy. Of course all this is arriving to the great chagrin of the US and other governments who have long insisted that the cannabinoids were dangerous drugs with no medical use. Many have pointed out that the evidence was quite the contrary and the next few decades will provide ample proof as they enter the mainstream of medicine.